Financing Announced for ADVANZ PHARMA

London – Paul Hastings LLP, a leading global finance firm, announced today that it has represented Morgan Stanley, Barclays, Goldman Sachs, Intesa SanPaolo, J.P. Morgan, Jefferies, and Royal Bank of Canada in connection with the issuance of €175.0 million in aggregate principal amount of euro-denominated 5% senior secured notes due 2028 (the “Notes”). The Notes are being offered as additional notes under the indenture dated as of April 1, 2021 pursuant to which the Issuer issued €475.0 million senior secured notes due 2023 and £335.0 million 6¼% senior secured notes due 2028.

Paul Hastings also represented the underwriting banks in relation to the €1.6 billion public-to-private financing provided in connection with Nordic Capital’s original acquisition of ADVANZ PHARMA in 2021. ADVANZ PHARMA is an international specialty pharmaceutical company focused on serving the needs of patients and healthcare providers around the world with continued access to high-quality, niche established medicines.

The Paul Hastings team in London was led by partners Luke McDougall and Ed Holmes with finance associates Andro Atlaga and Valmir Merkaj.

Dedicated to helping the world’s leading Wall Street and global investment banks, asset managers and corporations achieve their business and legal goals, Paul Hastings is a premier global finance law firm with elite teams in finance, mergers and acquisitions, private equity and litigation.

Our unmatched client service has helped us become one of the legal profession’s most admired firms, known for a diverse and highly collaborative culture that delivers innovative solutions.